<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>5</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kastritis, E.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Lenalidomide for the treatment of relapsed or refractory multiple myeloma</style></title><secondary-title><style face="normal" font="default" size="100%">Immunomodulating Drugs for the Treatment of Cancer</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84974603566&amp;partnerID=40&amp;md5=3a49116ab25b3f0f8344c99b299fc655</style></url></web-urls></urls><language><style face="normal" font="default" size="100%">eng</style></language><notes><style face="normal" font="default" size="100%">Export Date: 21 February 2017</style></notes></record></records></xml>